Addison's Disease Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Addison's Disease Treatment Market Analysis

Addison's Disease Treatment market is projected to register a CAGR of 4.1% during the forecast period (2022 - 2027).

COVID-19 pandemic has significantly impacted Addison's disease, a rare disease treatment market. The rise in COVID-19 cases has led to global healthcare services shifting their resources toward COVID-19 care while impacting patients with rare diseases. According to the Eurordis International Survey in February 2021, rare disease patients seemed to have a worse experience than chronic disease patients due to the pandemic. According to the article titled ' COVID-19 and the endocrine system: exploring the unexplore' published in May 2020, it has been found that the adrenal system is one of the most highly affected organ systems in the body during acute active infection in individuals with COVID-19 infection who require hospitalization. The pandemic led to the shutdown of companies and other non-healthcare businesses. The lack of healthcare services and canceled/postponed appointments result in the underdiagnosis of rare disease patients, negatively impacting the market.

The factors propelling the market's growth are rising incidences of Addison's disease globally, growing awareness regarding adrenal insufficiency, and rising healthcare expenditure in the countries.

The rising incidences of Addison's disease are the key factor driving the market's growth over the forecast period. According to an article "Adrenal Insufficiency in Patients," published in June 2021, it has been found that one in 10,000 newborns are affected by congenital adrenal hyperplasia, an inherited form of primary adrenal insufficiency. In addition, the increasing number of tuberculosis cases is also causing adrenal insufficiency disease among people. According to the statistics published by the Centers for Disease Control and Prevention (CDC) data updated in 2021, around 7,860 cases of tuberculosis were reported in the United States in 2021. In addition, about 13 million in the United States are affected by latent tuberculosis infection.

Similarly the article titled ' Adrenal Insufficiency and Addinon's Disease ' published in July 2020 mentioned that Addison's disease can affect all age groups, but the most common onset was at 30-50 years of age. The annual incidence of Addinson's disease was 4 in 1,000,000 peope in Western populations. Such incidence of addison's disease is expected to drive the demand for the effective treatmnet, thereby contributing to the growth of the market.

However, the high costs associated with the treatment medications, the lack of awareness among people regarding Addison's disease, and the inability to diagnose the disease early are likely to hinder the market's growth.

Addison's Disease Treatment Market Trends

This section covers the major market trends shaping the Addison's Disease Treatment Market according to our research experts:

Oral Route is Expected to Have the Significant Market Share

Addison's Disease Treatment Industry Segmentation

As per the report's scope, Addison's disease is a rare disorder in which the adrenal cortex fails to produce adequate glucocorticoids and mineralocorticoids to meet metabolic demands (primary adrenocortical insufficiency). The loss or primary dysfunction of the adrenal glands. The Global Addison's Disease Treatment Market is segmented by drug class ( Glucocorticoid, Mineralocorticoid, and Others), route of administration ( Oral, Parenteral, and Others), diagnosis (Laboratory Testing and Imaging Testing), end-user (Hospitals, Homecare, Specialty Clinics, and Others) and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, South America). The report offers the value (USD million) for the above segments.